Jennifer Bragg

I serve as head of Skadden’s Washington, D.C. Litigation practice. I am a nationally recognized lawyer advising Food and Drug Administration (FDA)-regulated companies facing government investigations and related enforcement challenges. Since serving in the FDA’s Office of Chief Counsel as associate chief counsel for enforcement, I have represented companies in investigations by the U.S. Department of Justice (DOJ) and the U.S. Department of Health and Human Services Office of Inspector General. This work also includes conducting internal investigations for companies that involve potential violations of relevant policies and procedures designed to ensure compliance with law. I also advise on corporate compliance program development and operations designed to mitigate the risk of fraud and abuse. I'm often called on to advise pharmaceutical and medical device companies in connection with complex regulatory issues in an effort to minimize litigation and enforcement risks, as well as overcome transactional hurdles. Additionally, I frequently conduct due diligence and related counseling in connection with transactions in the life sciences and health care industries, and have litigation and trial experience. I have been recognized in the highest band in Chambers USA for my work in the pharmaceutical and medical device space, in which sources report “she has a lot of business savvy and is very strategic and practical.” In addition, I have been named in The Best Lawyers in America every year since 2013 and was named a 2020 BTI Client Service All-Star. Additionally, I was named a 2021 Life Sciences MVP by Law360. I also was included in The Legal 500 U.S., Lawdragon 500 Leading Lawyers in America and repeatedly cited as a Star by LMG Life Sciences. I was named as an Expert in the 2019 edition of Who’s Who Legal: Life Sciences’ Regulatory chapter. I'm a proud member of Skadden’s Women’s Initiatives Committee, which promotes the retention and advancement of women in the firm. I'm also a member of the firm’s Hiring Committee. I'm a frequent speaker at leading industry conferences, including for the Food and Drug Law Institute (FDLI), AdvaMed and DRI. In certain jurisdictions, this may be considered attorney advertising.